Curis Raises $5.6 Million in Public Offering for Drug Development

The offering, priced at $1.50 per share and warrant, includes common warrants exercisable at $1.75 over a five-year period. Curis is also offering pre-funded warrants priced at $1.49 for investors opting against common stock. The transaction, managed by lead placement agent A.G.P./Alliance Global Partners and co-placement agent Laidlaw & Company (UK) Ltd., is slated to close on August 14, 2026, pending customary market conditions.

Proceeds from the sale will bolster the company's pipeline, specifically the development of emavusertib, a small molecule IRAK4 and FLT3 inhibitor. The drug is currently undergoing evaluation in the TakeAim Lymphoma and TakeAim CLL studies, aimed at treating relapsed or refractory central nervous system lymphoma and chronic lymphocytic leukemia. The company also intends to utilize these funds to sustain its ongoing acute myeloid leukemia research.